135
Participants
Start Date
October 25, 2017
Primary Completion Date
August 31, 2032
Study Completion Date
August 31, 2032
Ustekinumab
Participants will not receive any intervention as part of this study. Participants with moderate to severe plaque psoriasis who are initiating treatment with ustekinumab in clinical practice (patients should either start therapy with ustekinumab within 2 months after the first assessment in the study or have started therapy with ustekinumab in the 12-week period before the first assessment in the study for the treatment of psoriasis) will be observed for the long-term safety of ustekinumab and the long-term effects of ustekinumab on growth and development.
UCL Hopital Saint-Luc, Brussels
Gentofte Herlev Hospital, Hellerup
UZ Leuven, Leuven
CHU de Liège - Domaine Universitaire du Sart Tilman, Liège
Grand Hôpital de Charleroi, Loverval
Kinderspital Zürich, Zurich
Uniklinik Graz, Graz
Le Bateau Blanc, Martigues
Andreas Sygros Hospital, Athens
CHRU Besancon Hopital Jean Minjoz, Besançon
ICH Hopital A. Morvan, Brest
Groupe Hospitalier Pellegrin CHU de Bordeaux, Bordeaux
CHU Saint Etienne Hopital Nord, Saint-Etienne
Gemeinschaftspraxis Dres. Quist, Mainz
Universitatsmedizin der Johannes Gutenberg Universitat Mainz, Mainz
Hopital Necker Enfants Malades, Paris
Praxis Dr. med. Beate Schwarz - Germany, Langenau
CH Victor Dupouy Argenteuil, Argenteuil
Moscow Research-Practical Center of Dermatovenerology and Cosmetology, Moscow
FSBI 'Scientific Centre of Children Health' of the Russian Academy of Medical Sciences, Moscow
Saint-Petersburg State Pediatric Medical Academy of RosZdrav, Saint Petersburg
Llc Ultramed, Omsk
Bispebjerg Hospital, Copenhagen
University Hospital for Skin and Venereal Diseases, Thessaloniki
Radboudumc, Nijmegen
Oslo universitetssykehus HF, Rikshospitalet, Oslo
University Hospital of Wales, Cardiff
Whipps Cross University Hospital, London
Great Ormond Street Hospital, London
Salford Royal Hospital, Salford
Lead Sponsor
Janssen-Cilag International NV
INDUSTRY